Akiko Shinagawa

Akiko Shinagawa

Auto-generated profile, based on publicly available information

Akiko Shinagawa

Department of Obstetrics and Gynecology, Faculty of Medical Sciences University of Fukui Fukui Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2008 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
YYYoshio Yoshida
Yoshio Yoshida
TKTetsuji Kurokawa
Tetsuji Kurokawa
YSYoko Sawamura
Yoko Sawamura
ASAkiko Shinagawa
Akiko Shinagawa
TTTetsuya Tsujikawa
Tetsuya Tsujikawa
FKFumikazu Kotsuji
Fumikazu Kotsuji
The purpose of this study was to prospectively determine whether combined MRI and 18F-FDG PET is more accurate than MRI in assessing nonbenign uterine smooth muscle tumors (USMTs). Methods: Seventy patients (mean age, 49 ± 10 y; range, 28–77 y) suspected of having nonbenign USMTs underwent both MRI and 18F-FDG PET before surgery. Results were evaluated using receiver-operating-characteristic (ROC) analyses and the Cochran Q test. Results: The area under the ROC curve for MRI with 18F-FDG PET was significantly higher than that for MRI (0.97 vs. 0.89, P < 0.05). Although multiple comparisons using the Cochran Q test were not significant, the sensitivity, specificity, and accuracy for MRI with 18F-FDG PET with probable nonbenign USMT cases considered to be positive were higher than those for MRI (93.3% vs. 73.3%; 92.7% vs. 85.5%; and 92.9% vs. 82.9%, respectively). Conclusion: MRI with 18F-FDG PET is useful in assessing nonbenign USMTs, as compared with MRI.

1 December 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
KKKazumi Kurata
Kazumi Kurata
YCYoko Chino
Yoko Chino
ASAkiko Shinagawa
Akiko Shinagawa
TKTetsuji Kurokawa
Tetsuji Kurokawa
YYYoshio Yoshida
Yoshio Yoshida
The aim of this study was to determine whether a preoperative health status index and intraoperative data could predict perioperative morbidity and mortality in women over the age of 65 years undergoing surgery for gynecologic disorders. The medical records of 68 female patients who were ≥65 years of age and who underwent surgery under general anesthesia in our institute from January 2014 to December 2015 were retrospectively reviewed. Preoperative data were extracted from a database and included comorbidities, American Society of Anesthesiologists physiological status classification, the Charlson Comorbidity Index, the Subjective Global Assessment 2011 revision, the subjects' risk of falling, body mass index, and age. The intraoperative factors investigated included the type of surgery and the Surgical Apgar Score (SAS). Major postoperative complications were defined as > Grade 3 based on the Clavien-Dindo classification version 2.0. Of the 68 elderly gynecological patients, 6 (8.8%) developed serious Grade 3 or worse complications within 30 days of surgery. The only factor that significantly affected postoperative complications was the SAS, an index of the patient's intraoperative condition. The optimum cut-off SAS for the occurrence of complications was determined by the receiver operating characteristic curve to be ≤ 6 points; a score ≤6 points predicted the development of postoperative complications with 66.7% sensitivity and 79.0% specificity. In this study, the SAS predicted the development of serious complications in elderly gynecological patients within 30 days of surgery more accurately than did other comorbidities, preoperative assessments, and type of surgery.

18 August 2024 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Open access
SYShizuka Yamada
Shizuka Yamada
MOMakoto Orisaka
Makoto Orisaka
TKTetsuji Kurokawa
Tetsuji Kurokawa
Toshimichi OnumaToshimichi Onuma
Toshimichi Onuma
ASAkiko Shinagawa
Akiko Shinagawa
YYYoshio Yoshida
Yoshio Yoshida
Recent studies show increased expression of human epidermal growth factor receptor 2 (HER2) in cervical cancer, but the efficacy of anti‐HER2 therapy remains under‐researched. Here, we present a case of recurrent HER2‐positive serous carcinoma, presumably arising in the cervix, diagnosed by comprehensive genomic profiling, which responded to trastuzumab. The patient underwent a radical hysterectomy with concurrent adjuvant chemoradiotherapy. One year after surgery, the patient experienced recurrence (multiple lymph node metastases). She underwent chemotherapy and subsequent comprehensive genomic profiling, which revealed HER2 positivity. Despite treatment, the lymph node and peritoneal metastases progressed. Therefore, combination chemotherapy with paclitaxel and trastuzumab was initiated. Subsequently, the patient's clinical symptoms improved considerably, and good health was maintained for 8 months. This report highlights the importance of comprehensive genomic profiling and targeted therapies when standard treatments fail.

10 September 2022 in Health Evaluation and Promotion
Verified
Journal Article
Open access
PDF file
TKTetsuji Kurokawa
Tetsuji Kurokawa
Toshimichi OnumaToshimichi Onuma
Toshimichi Onuma
ASAkiko Shinagawa
Akiko Shinagawa
YCYoko Chino
Yoko Chino
YYYoshio Yoshida
Yoshio Yoshida
日本における子宮頸がん検診の問題点の一つは検診受診率の低さである。その問題点の解決策の一つとして、都合の良い時に都合の良い場所で行える自己採取HPV検査による検査の導入を考えた。本研究の目的は、自己採取HPV検査が住民に受け入れられることを確認することである。結果は、検診未受診者でも自己採取HPV検査なら10%程度は検査を受ける意思があることが確認できた。さらに、未受診者には高危険群HPVの陽性者が13.6%と高率に含まれていた。その希望者の中で、1%程度の前がん病変が発見された。今回の検討は、自己採取HPV検査の導入が子宮頸がん検診受診率の改善に寄与することが示唆された。